Fig. 4From: Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trialMean overall quality of life (QoL) score of mCRC patients over early study visits at baseline and during famitinib or placebo treatment. All data points are presented as mean ± standard deviationBack to article page